CytomX Therapeutics (NASDAQ:CTMX) Raised to “Neutral” at JPMorgan Chase & Co.

JPMorgan Chase & Co. upgraded shares of CytomX Therapeutics (NASDAQ:CTMX) from an underweight rating to a neutral rating in a research report released on Monday morning, MarketBeat.com reports.

CytomX Therapeutics Stock Performance

Shares of CTMX stock opened at $1.67 on Monday. CytomX Therapeutics has a fifty-two week low of $1.04 and a fifty-two week high of $2.86. The stock’s fifty day moving average price is $2.04 and its two-hundred day moving average price is $1.63. The company has a market cap of $113.11 million, a PE ratio of -83.46 and a beta of 1.01.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Monday, March 11th. The biotechnology company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.01). The company had revenue of $26.61 million during the quarter, compared to analyst estimates of $23.36 million. On average, equities analysts predict that CytomX Therapeutics will post -0.21 EPS for the current fiscal year.

Insider Transactions at CytomX Therapeutics

In related news, CEO Sean A. Mccarthy sold 20,223 shares of the firm’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $2.09, for a total transaction of $42,266.07. Following the sale, the chief executive officer now owns 524,481 shares of the company’s stock, valued at approximately $1,096,165.29. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last ninety days, insiders sold 35,024 shares of company stock worth $73,200. Corporate insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On CytomX Therapeutics

Several hedge funds have recently added to or reduced their stakes in CTMX. AlphaMark Advisors LLC increased its position in CytomX Therapeutics by 119.8% in the 4th quarter. AlphaMark Advisors LLC now owns 23,183 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 12,635 shares during the period. Congress Park Capital LLC lifted its holdings in shares of CytomX Therapeutics by 112.8% during the fourth quarter. Congress Park Capital LLC now owns 239,300 shares of the biotechnology company’s stock worth $371,000 after purchasing an additional 126,850 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in shares of CytomX Therapeutics by 737.4% in the third quarter. Bank of New York Mellon Corp now owns 266,836 shares of the biotechnology company’s stock worth $344,000 after purchasing an additional 234,970 shares during the last quarter. 67.77% of the stock is currently owned by institutional investors and hedge funds.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.